Clinical Trials Logo

Eye Diseases clinical trials

View clinical trials related to Eye Diseases.

Filter by:

NCT ID: NCT02284516 Completed - Dry Eye Disease Clinical Trials

A Study to Evaluate Efficacy and Safety of Lifitegrast in Subjects With Dry Eye (OPUS-3)

OPUS-3
Start date: November 6, 2014
Phase: Phase 3
Study type: Interventional

Evaluate the efficacy and safety of Lifitegrast in subjects with dry eye disease and a recent history of artificial tear use.

NCT ID: NCT02260960 Completed - Dry Eye Disease Clinical Trials

The Influence of PRN Dry Eye Omega-3 Nutritional Regimen on Tear Osmolarity In Cases Of Dry Eye Disease

Start date: March 2014
Phase: Phase 2/Phase 3
Study type: Interventional

The investigators hypothesize that oral omega-3-acid triglyceride form will decrease dry-eye related symptoms as well as clinical markers associated with dry eye disease (TearOsmolarity, Schirmer-1 test values, corneal staining, and fluorescein tear break-up time) when compared to administration of placebo.

NCT ID: NCT02254265 Completed - Dry Eye Disease Clinical Trials

Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca

Start date: September 2014
Phase: Phase 2/Phase 3
Study type: Interventional

This is a Phase 2/3 study to evaluate the safety and efficacy of 2 different dose concentrations of OTX-101 dosed twice a day in both eyes for 84 days compared to placebo (vehicle) in patients with keratoconjunctivitis sicca (dry eye disease).

NCT ID: NCT02252744 Completed - Clinical trials for Rheumatoid Arthritis

Prevalence of Dry Eye Disease in Patients Diagnosed With Rheumatoid Arthritis

Start date: November 2012
Phase: N/A
Study type: Observational

This study will evaluate the prevalence of dry eye disease in patients diagnosed with rheumatoid arthritis. No treatment is administered in this study.

NCT ID: NCT02242032 Completed - Dry Eye Disease Clinical Trials

Study of the Safety and Tolerability of P 321 Ophthalmic Solution in Subjects With Dry Eye Disease

Start date: July 2014
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety and tolerability of P-321 Ophthalmic Solution in subjects with mild to moderate dry eye disease.

NCT ID: NCT02229955 Completed - Dry Eye Syndromes Clinical Trials

Study of Tisporin Eye Drops Group and Restasis Eye Drops Group After Treatment, Each Treatment Group Comparisons for Evaluation of Efficacy and Safety in Moderate to Severe Dry Eye Disease

HL_TSPR_302
Start date: December 2013
Phase: Phase 3
Study type: Interventional

The purpose of this clinical Study is Tisporin Eye Drops 0.05%(Cyclosporine ophthalmic solution) group and Restasis Eye Drops 0.05%(Cyclosporine ophthalmic suspension) group 12 weeks after treatment, each treatment group comparisons for evaluation of efficacy and safety in Moderate to Severe Dry Eye Disease. - Corneal staining test, Ocular surface disease index (OSDI), Tear break up time (TBUT), Non-anesthetic Schirmer test

NCT ID: NCT02188160 Completed - Dry Eye Syndromes Clinical Trials

Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease

Kauai
Start date: June 2014
Phase: Phase 2
Study type: Interventional

The primary purpose of this study is to determine the efficacy and safety of KPI-121 0.25% ophthalmic suspension compared to vehicle (placebo) in subjects who have a documented clinical diagnosis of dry eye disease. The product will be studied over 28 days, with 1-2 drops instilled in each eye four times daily (QID).

NCT ID: NCT02157077 Completed - Clinical trials for Macular Degeneration

Aflibercept After Ranibizumab in Exudative Age-related Macular Degeneration

ARI2
Start date: December 2013
Phase: Phase 3
Study type: Interventional

The purpose of the current study is to evaluate the ability of Eylea to induce a regression of PED height on patients previously extensively treated by Lucentis. The regimen proposed for this study is the 3 monthly injection followed by a 6 weeks interval injection until week 26.

NCT ID: NCT02155049 Completed - Clinical trials for Thyroid Associated Ophthalmopathies

Treatment of Soft Tissue Expansion in Inactive Thyroid Eye Disease Patients Using Drops of Prostaglandin Analogues

Start date: November 2014
Phase: Phase 3
Study type: Interventional

Prostaglandin analogues eye drops are common and effective treatment for decreasing Intra-Ocular Pressure (IOP) in Glaucoma patients. A number of recently published case reports have documented periorbital fat atrophy following treatment by prostaglandin analogues. In this study the investigators want to use this side-effect of prostaglandin analogues for the treatment of orbital and periocular fat proliferation in inactive Thyroid eye disease (TED) patients, as a conservative substitute for surgical intervention.

NCT ID: NCT02136940 Completed - Glaucoma Clinical Trials

Multiple Dose-parallel-group Study of AMA0076 in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension

Start date: April 2014
Phase: Phase 2
Study type: Interventional

The objective of this parallel group study is to evaluate the safety, tolerability and efficacy of AMA0076 in reduction of intraocular pressure in subjects with primary open-angle glaucoma or ocular hypertension.